ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Results available

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

ClinicalTrials.gov ID: NCT03637491

Public ClinicalTrials.gov record NCT03637491. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS

Study identification

NCT ID
NCT03637491
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
36 participants

Conditions and interventions

Interventions

  • Avelumab Drug
  • Binimetinib Drug
  • Talazoparib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 14, 2018
Primary completion
Dec 2, 2020
Completion
Feb 1, 2021
Last update posted
Jan 25, 2022

2018 – 2021

United States locations

U.S. sites
11
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
Highlands Oncology Group Fayetteville Arkansas 72703
Highlands Oncology Group Rogers Arkansas 72758
Highlands Oncology Group Springdale Arkansas 72762
California Cancer Associates for Research and Excellence, Inc (cCARE) Encinitas California 92024
University of Colorado Denver CTO (CTRC) Aurora Colorado 80045
University of Colorado Hospital Aurora Colorado 80045
Horizon Oncology Research, LLC Lafayette Indiana 47905
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232
The University of Texas MD Anderson Cancer Center Houston Texas 77030
University of Utah, Huntsman Cancer Hospital Salt Lake City Utah 84112
University of Utah, Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03637491, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 25, 2022 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03637491 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →